Kiora Pharmaceuticals
KPRX
19 hedge funds and large institutions have $5.38M invested in Kiora Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
595% more capital inflows, than outflows
Capital inflows: $217K | Capital outflows: $31.2K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
12% more funds holding
Funds holding: 17 → 19 (+2)
1.6% more ownership
Funds ownership: 47.87% → 49.47% (+1.6%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ADAR1 Capital Management
Austin,
Texas
|
+$93.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$44.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$39.5K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$19.5K |
| 5 |
Stonepine Capital Management
Bend,
Oregon
|
+$9.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$31.1K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$74 |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$23 |
| 4 |
Activest Wealth Management
Aventure,
Florida
|
-$4 |
| 5 |
JP Morgan Chase
New York
|
-$4 |
KPRX Hedge Fund Activity: Q3 2024 in Review
19 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2024, worth a combined $5.38M — down 9.9% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KPRX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $93.5K. The largest seller was UBS Group, cutting an estimated $31.1K.
- 19 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2024, up from 17 in Q2 2024.
- Funds reported $5.38M of Kiora Pharmaceuticals stock for Q3 2024, down 9.9% quarter-over-quarter.
- 4 funds opened new Kiora Pharmaceuticals positions in Q3 2024 and 2 closed out, a net change of +2 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2024 was ADAR1 Capital Management, an estimated $93.5K added.
- The largest Kiora Pharmaceuticals seller in Q3 2024 was UBS Group, an estimated $31.1K sold.
Based on aggregated 13F filings for Q3 2024.